1. Home
  2. PLG vs CRBU Comparison

PLG vs CRBU Comparison

Compare PLG & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Platinum Group Metals Ltd. (Canada)

PLG

Platinum Group Metals Ltd. (Canada)

HOLD

Current Price

$1.65

Market Cap

223.4M

Sector

N/A

ML Signal

HOLD

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$2.23

Market Cap

192.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLG
CRBU
Founded
2000
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.4M
192.4M
IPO Year
2002
2021

Fundamental Metrics

Financial Performance
Metric
PLG
CRBU
Price
$1.65
$2.23
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.75
AVG Volume (30 Days)
1.4M
1.5M
Earning Date
04-10-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.64
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.63
Revenue Next Year
N/A
$10.93
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.35
$0.96
52 Week High
$4.04
$3.53

Technical Indicators

Market Signals
Indicator
PLG
CRBU
Relative Strength Index (RSI) 43.67 61.96
Support Level $1.65 $1.73
Resistance Level $1.73 $2.28
Average True Range (ATR) 0.11 0.15
MACD -0.01 0.01
Stochastic Oscillator 25.00 82.11

Price Performance

Historical Comparison
PLG
CRBU

About PLG Platinum Group Metals Ltd. (Canada)

Platinum Group Metals Ltd is a development-stage company, conducts work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa. Key metals of economic interest on the company's mineral properties include platinum, palladium, rhodium, gold, copper, and nickel. The company operates in one segment, the development of the Waterberg Project in South Africa, and geographically in Canada and South Africa.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Share on Social Networks: